60 Recruiting Advanced Solid Tumors Phase 1 Clinical Trials
Active phase 1 studies for advanced solid tumors enrolling across the USA. Verify eligibility and contact site coordinators.
All Advanced Solid Tumors studiesPhase 1 Studies for Advanced Solid Tumors
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
📍 HonorHealth — Scottsdale, Arizona
View Study & Checklist ➔A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
📍 University of California Irvine Chao Family Comprehensive Cancer Center — Orange, California
View Study & Checklist ➔QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
📍 Sarah Cannon Research Institute — Denver, Colorado
View Study & Checklist ➔A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
📍 Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's — Denver, Colorado
View Study & Checklist ➔A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer
📍 Honor Health Research Institute — Scottsdale, Arizona
View Study & Checklist ➔A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
📍 Local Institution - 0021 — Los Angeles, California
View Study & Checklist ➔A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
📍 Arizona Clinical Research Center, Inc.;Hematology Oncology Physicians - Aoa — Tucson, Arizona
View Study & Checklist ➔Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
📍 Arizona Oncology Associates Professional Corporation — Tucson, Arizona
View Study & Checklist ➔Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
📍 Banner MD Anderson Cancer Ctr /ID# 260129 — Gilbert, Arizona
View Study & Checklist ➔Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
📍 Columbia University Medical Center — New York, New York
View Study & Checklist ➔A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
📍 Valkyrie Clinical Trials — Los Angeles, California
View Study & Checklist ➔A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
📍 The University of Chicago Medical Center - Hyde Park - Hematology & Oncology — Chicago, Illinois
View Study & Checklist ➔A Study of ZW191 in Participants With Solid Tumors
📍 Yale University — New Haven, Connecticut
View Study & Checklist ➔A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
📍 Research Site — Birmingham, Alabama
View Study & Checklist ➔A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
📍 Local Institution - 0003 — Tucson, Arizona
View Study & Checklist ➔A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.
📍 NEXT Oncology- Virginia — Fairfax, Virginia
View Study & Checklist ➔First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
📍 Research Site — Scottsdale, Arizona
View Study & Checklist ➔A Study of MGC028 in Participants With Advanced Solid Tumors
📍 UCSF - Helen Diller Family Cancer Center — San Francisco, California
View Study & Checklist ➔A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
📍 Moffitt Cancer Center ( Site 0261) — Tampa, Florida
View Study & Checklist ➔Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
📍 The Angeles Clinic and Research Institute — Los Angeles, California
View Study & Checklist ➔A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
📍 START Los Angeles — Los Angeles, California
View Study & Checklist ➔Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
📍 Honor Health — Scottsdale, Arizona
View Study & Checklist ➔Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
📍 Stanford Cancer Center — Palo Alto, California
View Study & Checklist ➔Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
📍 University of Colorado Hospital - Anschutz Cancer Pavilion — Aurora, Colorado
View Study & Checklist ➔An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
📍 Teva Investigational Site 12017 — Los Angeles, California
View Study & Checklist ➔First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
📍 University of Colorado Denver — Aurora, Colorado
View Study & Checklist ➔A Study of ASP1002 in Adults for Treatment of Solid Tumors
📍 Yale University Cancer Center — New Haven, Connecticut
View Study & Checklist ➔A Clinical Study of YL205 in Patients With Advanced Solid Tumors
📍 Sarah Cannon Research Institute (SCRI)- Denver — Denver, Colorado
View Study & Checklist ➔A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
📍 Cedars Sinai Medical Center — Los Angeles, California
View Study & Checklist ➔A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
📍 Research Site — Huntersville, North Carolina
View Study & Checklist ➔A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
📍 Research Site 111 — Tucson, Arizona
View Study & Checklist ➔A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
📍 Sarah Cannon Research Institute at HealthOne — Denver, Colorado
View Study & Checklist ➔Study of FID-022 in Participants With Advanced Solid Tumors
📍 USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California
View Study & Checklist ➔Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
📍 The Lindner Center for Research & Education at The Christ Hospital — Cincinnati, Ohio
View Study & Checklist ➔A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
📍 Honorhealth Research Institute — Scottsdale, Arizona
View Study & Checklist ➔A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
📍 Gabrail Cancer Center — Ohio City, Ohio
View Study & Checklist ➔A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
📍 Stanford University Medical Center — Palo Alto, California
View Study & Checklist ➔A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
📍 Local Institution - 0007 — Los Angeles, California
View Study & Checklist ➔A Study of PHST001 in Advanced Solid Tumors
📍 Precision NextGen Oncology & Research Center — Beverly Hills, California
View Study & Checklist ➔A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
📍 The University of Alabama at Birmingham ( Site 1005) — Birmingham, Alabama
View Study & Checklist ➔A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
📍 University of California, Irvine (UCI) Health - UC Irvine Medical Center — Irvine, California
View Study & Checklist ➔A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
📍 Mayo Clinic Jacksonville — Jacksonville, Florida
View Study & Checklist ➔A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
📍 START Los Angeles, LLC — Los Angeles, California
View Study & Checklist ➔Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
📍 Hoag Memorial Hospital Presbyterian — Newport Beach, California
View Study & Checklist ➔A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
📍 Columbia University Irving Medical Center — New York, New York
View Study & Checklist ➔A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
📍 Next Oncology — San Antonio, Texas
View Study & Checklist ➔JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
📍 Mayo Clinic — Rochester, Minnesota
View Study & Checklist ➔A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
📍 The City of Hope National Medical Center — Duarte, California
View Study & Checklist ➔EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
📍 Morristown Medical Center — Morristown, New Jersey
View Study & Checklist ➔A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
📍 University of Arizona Cancer Center — Tucson, Arizona
View Study & Checklist ➔Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
📍 Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
View Study & Checklist ➔Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
📍 Yale University — New Haven, Connecticut
View Study & Checklist ➔Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
📍 University of Kansas — Fairway, Kansas
View Study & Checklist ➔First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
📍 Yale Cancer Center — New Haven, Connecticut
View Study & Checklist ➔A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
📍 Yale Cancer Center — New Haven, Connecticut
View Study & Checklist ➔Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
📍 TOI Clinical Research — Cerritos, California
View Study & Checklist ➔Study of GS-2426 in Participants With Advanced Solid Tumors
📍 START Midwest — Grand Rapids, Michigan
View Study & Checklist ➔